When we talk about precision oncology, we usually talk about breakthroughs. But behind every advancement in targeted therapies and genomic profiling lies a quieter reality: Most patients in the world still can’t reliably access the tests that unlock these headline treatments. 

This week on Within Reach, Clare Jones and Andrea Stevens expose the real bottlenecks - cost and reimbursement, fragmented infrastructure, uneven education, and policy blind spots - and explain why single-gene testing is no longer good enough. Together, they map out what it will take to move from isolated success stories, to a future where tailored cancer care is the standard, not the exception.

🔗 Connect with us

Clare Jones: https://www.linkedin.com/in/clarejonesprmamarketaccess/

Andrea Stevens: https://www.linkedin.com/in/andrea-l-stevens-phd/

Precision Cancer Consortium: https://www.precisioncancerconsortium.com/

Within Reach: https://withinreach.avalerehealth.com/ 

Avalere Health: https://avalerehealth.com/

https://www.linkedin.com/company/avalerehealth/

Evan Young: https://www.linkedin.com/in/evan-young-sxp/